Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Fidelity® Select Biotechnology Portfolio (FBIOX)

Net Asset Value
1 Day
Overall Morningstar Rating
Style or Category
No Load
Sales Expenses
Expense Ratio
Morningstar Risk Rating™
Investment Objective The investment seeks capital appreciation. The fund invests primarily in common stocks. It normally invests at least 80% of assets in securities of companies principally engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes and companies that benefit significantly from scientific and technological advances in biotechnology. The fund invests in domestic and foreign issuers. It uses fundamental analysis of factors such as each issuer's financial condition and industry position, as well as market and economic conditions to select investments. The fund is non-diversified.


1 month+1.50% 3 years+12.44%
3 months+11.75% 5 years+20.84%
1 year+16.07% Since inception+13.59%
Data through --

Peer Comparisonvs. Health

Performance 5-yr return+20.84%+16.30%
Expense ratio0.73%1.33%
Risk 5 year sharpe ratio0.841.05
Net assets$9.4B$3.0B
Average market cap$7.1B$29.5B
Average P/E--24.1
Portfolio turnover35%35%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyFidelity Investments
Fund manager & tenureRajiv Kaul / 11 Years
Minimal initial investment$2,500.00
Minimum IRA investment$2,500.00


U.S. stock95.45%
International stock4.28%
Fixed income0.00%
Top 5 Sectors
Portfolio weighting
Healthcare 100.00%
Business service 0.00%
Consumer goods 0.00%
Consumer service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
AMGN Amgen9.86%
ALXN Alexion Pharmaceuticals Inc6.06%
CELG Celgene5.51%
REGN Regeneron Pharmaceuticals4.74%
BIIB Biogen4.13%
VRTX Vertex Pharmaceuticals Inc2.70%
INCY Incyte Corp2.47%
SGEN Seattle Genetics Inc2.10%
BMRN Biomarin Pharmaceutical Inc1.94%